Anchor Therapeutics is a venture-backed, pre-clinical stage company. We are developing first-in-class novel allosteric GPCR modulators, called pepducins, to address intractable targets in several therapeutic areas including cancer, inflammation, metabolism, heart disease and pain.
|Primary Business Focus||Biotechnology - Pharmaceutical|
|No. of Employees at this location||21|
|Total Number Employees||21|
|Thomas McMurry||Interim President/SVP Preclinical R&D|
* Downloads will not contain Personnel E-mail addresses
|Focus||Biotechnology - Pharmaceutical|
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of American City Business Journals.